secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOXYTRAN, INC (BIXT)
CIK:        0001445815
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0001493152-22-020817
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bioxytran publishes positive peer-reviewed data for ProLectin-M and PLG-007 drug candidates
--------------------------------------------------------------------------------

- August 1, 2022 article in Int. J. Health Sciences: ProLectin-M blocks SARS-CoV-2 in vitro; all 5 COVID-19 patients achieved complete remission, zero hospitalization.
- July 13, 2022 article in Int. J. Molecular Science: PLG-007 component GMα competitively inhibits α-amylase, maltase, and lactase with Ki of 2.1×10^-6M.
- Press release issued August 1, 2022 announcing the ProLectin-M peer-reviewed article and supporting mechanism of action data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222020817/0001493152-22-020817-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1445815/000149315222020817/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-020817

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer